Cytokinetics
CYTK
85 hedge funds and large institutions have $155M invested in Cytokinetics in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 12 closing their positions.
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
5% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $2.06M
0% more funds holding
Funds holding: 85 → 85 (0)
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
4.12% less ownership
Funds ownership: 54.12% → 49.99% (-4.1%)
12% less capital inflows, than outflows
Capital inflows: $9M | Capital outflows: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$3.93M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$558K |
| 3 |
BlackRock Fund Advisors
San Francisco,
California
|
+$549K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$478K |
| 5 |
Russell Frank Company
Seattle,
Washington
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.03M |
| 2 |
Renaissance Technologies
New York
|
-$1.75M |
| 3 |
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.12M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$993K |
| 5 |
Morgan Stanley
New York
|
-$679K |
CYTK Hedge Fund Activity: Q4 2014 in Review
85 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2014, worth a combined $155M — up 122% from $69.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CYTK positions and 12 closed out — a net gain of 2 holders — while 29 added to existing stakes and 29 trimmed.
The largest buyer was BVF Inc, adding an estimated $3.93M. The largest seller was Fidelity Investments, cutting an estimated $2.03M.
- 85 institutional investors held Cytokinetics (CYTK) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $155M of Cytokinetics stock for Q4 2014, up 122% quarter-over-quarter.
- 14 funds opened new Cytokinetics positions in Q4 2014 and 12 closed out, a net change of +2 holders.
- The largest Cytokinetics buyer in Q4 2014 was BVF Inc, an estimated $3.93M added.
- The largest Cytokinetics seller in Q4 2014 was Fidelity Investments, an estimated $2.03M sold.
Based on aggregated 13F filings for Q4 2014.